1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol, 2019, 30(8): 1194-1220.
|
3. |
Choong GM, Cullen GD, O’Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin, 2020, 70(5): 355-374.
|
4. |
Sapino A, Goia M, Recupero D, et al. Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol, 2013, 3: 129.
|
5. |
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med, 2018, 142(11): 1364-1382.
|
6. |
Onsum MD, Geretti E, Paragas V, et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol, 2013, 183(5): 1446-1460.
|
7. |
Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study. J Clin Oncol, 2020, 38(17): 1887-1896.
|
8. |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版). 中国癌症杂志, 2021, 31(10): 954-1040.
|
9. |
李健斌, 江泽飞. 2021年中国临床肿瘤学会乳腺癌诊疗指南更新要点解读. 中华医学杂志, 2021, 101(24): 1835-1838.
|
10. |
中国临床肿瘤学会乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会. 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版). 中华医学杂志, 2021, 101(17): 1226-1231.
|
11. |
中国癌协会乳腺癌专业委员会. 中国抗癌办会乳腺癌诊治指南与规范(2019年版). 中国癌症杂志, 2019, 29(8): 609-680.
|
12. |
Krop IE, LoRusso P, Miller KD, et al. A phase Ⅱ study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol, 2012, 30(26): 3234-3241.
|
13. |
Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase Ⅱstudy of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol, 2011, 29(4): 398-405.
|
14. |
Baselga J, Lewis Phillips GD, Verma S, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase Ⅲ study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res, 2016, 22(15): 3755-3763.
|
15. |
Kim SB, Wildiers H, Krop IE, et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase Ⅲ study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer. Int J Cancer, 2016, 139(10): 2336-2342.
|
16. |
Lee CK, Davies L, Gebski VJ, et al. Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer. J Clin Oncol, 2016, 34(9): 936-944.
|
17. |
Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol, 2020, 38(17): 1951-1962.
|
18. |
Shui R, Liang X, Li X, et al. Hormone receptor and human epidermal growth factor receptor 2 detection in invasive breast carcinoma: a retrospective study of 12 467 patients from 19 Chinese representative clinical centers. Clin Breast Cancer, 2020, 20(1): e65-e74.
|
19. |
Lambein K, Van Bockstal M, Vandemaele L, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol, 2013, 140(4): 561-566.
|
20. |
Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, et al. Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. Br J Cancer, 2020, 122(3): 397-404.
|
21. |
Jensen K, Krusenstjerna-Hafstrøm R, Lohse J, et al. A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2. Mod Pathol, 2017, 30(2): 180-193.
|
22. |
Modi S, Glass B, Prakash A, et al. Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit. 2020ESMO. Abstract 286P. https://www.annalsofoncology.org/article/S0923-7534(20)40384-9/fulltext.
|
23. |
Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer, 2021, 7(1): 1. doi: 10.1038/s41523-020-00208-2.
|
24. |
Dehghani M, Keshavarz P, Talei A, et al. The effects of low HER2/neu expression on the clinicopathological characteristics of triple-negative breast cancer patients. Asian Pac J Cancer Prev, 2020, 21(10): 3027-3032.
|
25. |
Plasilova ML, Hayse B, Killelea BK, et al. Features of triple-negative breast cancer: Analysis of 38 813 cases from the national cancer database. Medicine (Baltimore), 2016, 95(35): e4614. doi: 10.1097/MD.0000000000004614.
|
26. |
Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol, 2021, 22(8): 1151-1161.
|
27. |
Reinert T, Sartori GP, Souza AAB et al . Abstract PS4-22: Prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer. Cancer Res, https://aacrjournals.org/ cancerres/ article/81/4_Supplement/PS4-22/648803/Abstract-PS4-22-Prevalence-of-HER2-low-and-HER2.
|
28. |
de Moura Leite L, Cesca MG, Tavares MC, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat, 2021, 190(1): 155-163.
|